Q-omics provides the consensus-scored TRAJ57 profile across patient tissues and cancer cell-line models. TRAJ57 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRAJ57 is differentially expressed in 2, with the highest sampling consensus in READ. Additionally, TRAJ57 RNA expression shows 8,325 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, READ, and LSCC as cancer lineages where TRAJ57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ57 survival associations across molecular data types. TRAJ57 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ57 RNA expression–survival associations across cancer types. High TRAJ57 expression shows unfavorable associations in UVM, OV, KIRC and LUSC, but favorable associations in ESCA and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for TRAJ57 RNA expression.
This table summarizes TRAJ57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ57 shows lower tumor expression in KIRC and higher tumor expression in READ. The READ box plot shows higher TRAJ57 RNA expression in tumor versus normal tissue (log2 FC = +0.747, t-test p = .022).
This table shows molecular features associated with TRAJ57 in patient tissues and cancer cell lines. In patient samples, TRAJ57 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
